Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:623417.
doi: 10.1155/2012/623417. Epub 2012 May 10.

Hyperthermic intraoperative thoracoabdominal chemotherapy

Paul H Sugarbaker  1 , David Chang, O Anthony Stuart
Affiliations

Hyperthermic intraoperative thoracoabdominal chemotherapy

Paul H Sugarbaker et al. Gastroenterol Res Pract. 2012.

Abstract

Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option for selected patients with pseudomyxoma peritonei (PMP) and diffuse malignant peritoneal mesothelioma (DMPM). Tumor infiltration of the hemidiaphragm requiring partial resection occurs as a result of large volume and/or invasive disease at this anatomic site. Transmission of disease from abdomen to chest is a great danger in this group of patients. From a prospective database, patients who had diaphragm resection and then hyperthermic thoracoabdominal chemotherapy (HITAC) as a component of a cytoreductive surgical procedure were identified. Data from control patients receiving HIPEC or hyperthermic intrathoracic chemotherapy (HITOC) were analyzed for comparison. The morbidity, mortality, survival, and recurrence rate within the thoracic space were presented. Thirty patients had partial resection of a hemidiaphragm as part of a cytoreductive surgical procedure that utilized HITAC. The pharmacologic benefit of intracavitary chemotherapy administration was documented with an area under the curve ratio of intracavitary concentration times time to plasma concentration times time of 27 ± 10 for mitomycin C and 75 ± 26 for doxorubicin. Comparing percent chemotherapy absorbed for a ninety-minute treatment showed the largest for HIPEC, then for HITAC, and lowest for HITOC. The incidence of grade 3 and 4 adverse events was 43%. There was no mortality. Adjustments in the chemotherapy dose are not necessary with HITAC. The morbidity was high, the survival was acceptable, and intrathoracic recurrence was low.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pharmacokinetics of mitomycin C in 12 patients with simultaneous intraabdominal and intrathoracic chemotherapy used in conjunction with cytoreductive surgery.
Figure 2
Figure 2
Pharmacokinetics of doxorubicin in 12 patients with simultaneous intraabdominal and intrathoracic chemotherapy administration in conjunction with cytoreductive surgery.
Figure 3
Figure 3
Comparison of percent mitomycin C absorbed after 90 minutes of treatment from the abdominal cavity, combined thoracic and abdominal cavity, and the thoracic cavity alone.
Figure 4
Figure 4
Comparison of percent of doxorubicin absorbed after 90 minutes of treatment from the abdominal cavity, thoracic and abdominal cavity, and the thoracic cavity alone.
Figure 5
Figure 5
Survival for 29 patients who had a resection of the diaphragm as part of the cytoreductive surgical procedure combined with hyperthermic intraoperative thoracoabdominal chemotherapy (HITAC). (a) appendiceal malignancy (N = 16), (b) peritoneal mesothelioma (N = 8), and (c) colon cancer (N = 5).
See this image and copyright information in PMC

References

    1. Sugarbaker PH. Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer Research in Cancer. 2009;3:179–203. - PubMed
    1. Glehen O, Gilly FN, Boutitie F, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1290 patients. Cancer. 2010;116(24):5608–5618. - PubMed
    1. Youssef H, Newman C, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin. Diseases of the Colon and Rectum. 2011;54(3):293–299. - PubMed
    1. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. Journal of Clinical Oncology. 2009;27(5):681–685. - PubMed
    1. Yan TD, Black D, Sugarbaker PH, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Annals of Surgical Oncology. 2007;14(10):2702–2713. - PubMed

LinkOut - more resources